BRPI0814403A2 - Devirados de imidazol como antagonistas de receptor ccr2 - Google Patents
Devirados de imidazol como antagonistas de receptor ccr2Info
- Publication number
- BRPI0814403A2 BRPI0814403A2 BRPI0814403-6A2A BRPI0814403A BRPI0814403A2 BR PI0814403 A2 BRPI0814403 A2 BR PI0814403A2 BR PI0814403 A BRPI0814403 A BR PI0814403A BR PI0814403 A2 BRPI0814403 A2 BR PI0814403A2
- Authority
- BR
- Brazil
- Prior art keywords
- devoid
- imidazole
- receptor antagonists
- ccr2 receptor
- ccr2
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
- 102000004497 CCR2 Receptors Human genes 0.000 title 1
- 108010017312 CCR2 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07111552 | 2007-07-02 | ||
| PCT/EP2008/057934 WO2009003861A1 (en) | 2007-07-02 | 2008-06-23 | Imidazole derivatives as ccr2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814403A2 true BRPI0814403A2 (pt) | 2015-01-27 |
Family
ID=39789741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814403-6A2A BRPI0814403A2 (pt) | 2007-07-02 | 2008-06-23 | Devirados de imidazol como antagonistas de receptor ccr2 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7935707B2 (pt) |
| EP (1) | EP2173735B1 (pt) |
| JP (1) | JP5431316B2 (pt) |
| KR (1) | KR101171480B1 (pt) |
| CN (1) | CN101687844B (pt) |
| AR (1) | AR067390A1 (pt) |
| AT (1) | ATE540942T1 (pt) |
| AU (1) | AU2008270438B2 (pt) |
| BR (1) | BRPI0814403A2 (pt) |
| CA (1) | CA2691662A1 (pt) |
| CL (1) | CL2008001946A1 (pt) |
| ES (1) | ES2377423T3 (pt) |
| IL (1) | IL202657A0 (pt) |
| MX (1) | MX2009014002A (pt) |
| PE (1) | PE20090546A1 (pt) |
| RU (1) | RU2010103104A (pt) |
| TW (1) | TWI357814B (pt) |
| WO (1) | WO2009003861A1 (pt) |
| ZA (1) | ZA200909163B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1976828T3 (en) | 2005-12-29 | 2017-03-06 | Celtaxsys Inc | DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE |
| US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
| JP2011518130A (ja) | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト |
| MX2010014172A (es) | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| EA020548B1 (ru) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
| PE20121614A1 (es) | 2009-12-17 | 2012-12-21 | Boehringer Ingelheim Int | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 |
| AU2011203649A1 (en) | 2010-01-06 | 2012-06-14 | Brickell Biotech, Inc. | DP2 antagonist and uses thereof |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| JP5786258B2 (ja) * | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なｃｃｒ２拮抗薬 |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| BR112015003729A2 (pt) * | 2012-08-24 | 2018-06-05 | Univ Texas | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente |
| JP6527851B2 (ja) | 2013-03-12 | 2019-06-05 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素を阻害する方法 |
| EP2968265A4 (en) | 2013-03-14 | 2016-12-28 | Celtaxsys Inc | INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE |
| KR20150127245A (ko) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| AU2014239567B2 (en) | 2013-03-14 | 2017-12-14 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
| BR112015030315B1 (pt) * | 2013-06-12 | 2022-10-04 | Kaken Pharmaceutical Co., Ltd | Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4 |
| WO2015130790A2 (en) | 2014-02-25 | 2015-09-03 | Board Of Regents, University Of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
| CA2990460C (en) | 2015-07-02 | 2023-10-17 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate |
| CN105017046A (zh) * | 2015-07-15 | 2015-11-04 | 上海博康精细化工有限公司 | 一种4-环丙胺基丁酸乙酯的制备方法 |
| CN116731101A (zh) | 2016-06-01 | 2023-09-12 | 雅斯娜 | 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物 |
| AU2017370937A1 (en) | 2016-12-07 | 2019-05-30 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7386815B2 (ja) | 2018-05-31 | 2023-11-27 | セルタクシー、エルエルシー | 呼吸器疾患患者の肺増悪を軽減する方法 |
| EP3883636A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000816A1 (en) | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| DE19832428A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| SE9902765D0 (sv) * | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| DE10032568A1 (de) * | 2000-07-05 | 2002-01-24 | Nmi Univ Tuebingen | Vorrichtung und Verfahren zum elektrischen Kontaktieren von in einer Flüssigkeit in Suspension befindlichen biologischen Zellen |
| ES2256560T3 (es) * | 2001-10-12 | 2006-07-16 | Bayer Pharmaceuticals Corporation | Heterociclos de 5 mienbros que contienen nitrogeno sustituidos con felino para el tratamiento de la obesidad. |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| US7728009B1 (en) | 2005-02-18 | 2010-06-01 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
-
2008
- 2008-06-23 BR BRPI0814403-6A2A patent/BRPI0814403A2/pt not_active IP Right Cessation
- 2008-06-23 RU RU2010103104/04A patent/RU2010103104A/ru not_active Application Discontinuation
- 2008-06-23 KR KR1020107002351A patent/KR101171480B1/ko not_active Expired - Fee Related
- 2008-06-23 ES ES08774212T patent/ES2377423T3/es active Active
- 2008-06-23 MX MX2009014002A patent/MX2009014002A/es active IP Right Grant
- 2008-06-23 AT AT08774212T patent/ATE540942T1/de active
- 2008-06-23 CA CA002691662A patent/CA2691662A1/en not_active Abandoned
- 2008-06-23 WO PCT/EP2008/057934 patent/WO2009003861A1/en not_active Ceased
- 2008-06-23 AU AU2008270438A patent/AU2008270438B2/en not_active Ceased
- 2008-06-23 EP EP08774212A patent/EP2173735B1/en not_active Not-in-force
- 2008-06-23 CN CN2008800222230A patent/CN101687844B/zh not_active Expired - Fee Related
- 2008-06-23 JP JP2010513872A patent/JP5431316B2/ja not_active Expired - Fee Related
- 2008-06-25 US US12/215,104 patent/US7935707B2/en not_active Expired - Fee Related
- 2008-06-30 PE PE2008001116A patent/PE20090546A1/es not_active Application Discontinuation
- 2008-07-01 CL CL2008001946A patent/CL2008001946A1/es unknown
- 2008-07-01 TW TW097124782A patent/TWI357814B/zh not_active IP Right Cessation
- 2008-07-01 AR ARP080102845A patent/AR067390A1/es unknown
-
2009
- 2009-12-10 IL IL202657A patent/IL202657A0/en unknown
- 2009-12-22 ZA ZA2009/09163A patent/ZA200909163B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR067390A1 (es) | 2009-10-07 |
| AU2008270438A1 (en) | 2009-01-08 |
| ZA200909163B (en) | 2012-05-30 |
| JP5431316B2 (ja) | 2014-03-05 |
| WO2009003861A1 (en) | 2009-01-08 |
| TW200908966A (en) | 2009-03-01 |
| ATE540942T1 (de) | 2012-01-15 |
| JP2010531835A (ja) | 2010-09-30 |
| CL2008001946A1 (es) | 2009-05-29 |
| CN101687844B (zh) | 2013-11-13 |
| TWI357814B (en) | 2012-02-11 |
| EP2173735A1 (en) | 2010-04-14 |
| US20090012063A1 (en) | 2009-01-08 |
| ES2377423T3 (es) | 2012-03-27 |
| IL202657A0 (en) | 2010-06-30 |
| AU2008270438B2 (en) | 2013-10-10 |
| CA2691662A1 (en) | 2009-01-08 |
| CN101687844A (zh) | 2010-03-31 |
| PE20090546A1 (es) | 2009-05-09 |
| US7935707B2 (en) | 2011-05-03 |
| KR20100028662A (ko) | 2010-03-12 |
| MX2009014002A (es) | 2010-01-28 |
| KR101171480B1 (ko) | 2012-08-07 |
| RU2010103104A (ru) | 2011-08-10 |
| EP2173735B1 (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814403A2 (pt) | Devirados de imidazol como antagonistas de receptor ccr2 | |
| BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
| BRPI0717023A2 (pt) | Tiazol pirazolopirimidina como antagonistas do receptor de crf1 | |
| BRPI0821141A2 (pt) | Derivados de heteroarila como antagonistas do receptor de orexina | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| PL2513093T3 (pl) | Nowi antagoniści receptora CCR2 i ich zastosowanie | |
| EP2150115A4 (en) | CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| BR112012010502A2 (pt) | derivados de benzimidazol-imidazol | |
| BRPI0919844A2 (pt) | compostos de azaindazol como antagonistas do receptor ccr1 | |
| RU2458924C3 (ru) | Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов | |
| CR10249A (es) | Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| BRPI0815948A2 (pt) | "compostos heterocíclicos como antagonistas de receptorncrth2" | |
| BRPI0814767A2 (pt) | Derivados de monoamida como antagonistas do receptor de orexina | |
| BRPI0818855A2 (pt) | Derivados de imidazol | |
| BRPI0815658A2 (pt) | Aril-éter pirrolidina como antagonistas do receptor nk3 | |
| ATE519738T1 (de) | Pyrrolidinarylether als nk3-rezeptorantagonisten | |
| BRPI0720078A2 (pt) | 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a) | |
| BRPI0814806A2 (pt) | Pirazinas substituídas como antagonistas de cb1 | |
| CU23857B1 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| IL213250A0 (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
| BRPI0807913A2 (pt) | Derivado heterocíclicos como receptores muscarínicos m3 | |
| BRPI1013617A2 (pt) | derivados de piperidina como antagonistas de receptor de nk3 | |
| BR112012003976A2 (pt) | antagonistas de receptor glyt1 carbocíclico | |
| BRPI0809641A2 (pt) | Pirimidinil-piperazinas úteis como ligantes do receptor d3/d2hu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |